Study Summary: This research study is testing a new treatment called BMS-986368 for people with Alzheimer's Disease who experience agitation. Agitation means feeling restless, upset, or annoyed. BMS-986368 is a type of medicine known as a FAAH/MAGL inhibitor, which means it helps control certain chemicals in the brain that might affect mood and behavior. Eligibility: Participants must have Alzheimer's Disease confirmed by specific tests and must have shown signs of agitation for at least four weeks. They should live in a stable environment like a nursing home, assisted living, or their own home with a caregiver. They must be able to move around by themselves, even if they need help like a wheelchair. Exclusion: People with severe mental health issues, like hallucinations or certain disorders, cannot join. Participants should not have had serious depression with psychotic features or delirium recently. Key Points:

• The study is focused on safety and effectiveness of the treatment.
• Participants need a caregiver to help them during the study.
• People with certain mental health issues are not eligible.